Alpha Dart Therapy Shows Complete Tumor Clearance in Five Brain Cancer Patients
Reported Sunday, Alpha Tau’s Alpha DaRT Achieves 100% Feasibility In 8 Recurrent Glioblastoma Patients, With Five Complete Responses And One Partial Response Among Six Evaluable Patients And No Unanticipated Serious Adverse Events
Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events - Conference Call Scheduled for 8:30am ET November 16
Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN Trial
Piper Sandler Upgrades Alpha Tau Medical to Overweight, Raises Price Target to $22
Alpha Tau Medical (DRTS) Stock May Be Hard To Justify Despite Its 343% Run
Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange
Alpha Tau Medical To Join TASE’s TA-90 and TA-125 Indices On November 5, 2026
Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea
Alpha Tau Medical Inks MoU With Samsung Medical Center In Seoul Regarding Potential Clinical Study In Pancreatic Cancer Patients
How Investors Are Reacting To Alpha Tau Medical (DRTS) Expanded Brain Cancer Trial
HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $16 Price Target
Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting
Alpha Tau Medical Receives FDA Approval For Investigational Device Exemption Supplement To Expand Its U.S. REGAIN Study
Alpha Tau to Participate in October Investor Conferences
Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough
Barclays Maintains Overweight on Alpha Tau Medical, Raises Price Target to $30
Alpha Tau to Participate in September Investor Conferences
Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.